Authority: 49 U.S.C. 40103, 40113, 40120, 44701; 49 U.S.C. 106(g); and 14 CFR 11.49(b)(2).

2. Part 97 is amended to read as follows:

§§ 97.23, 97.25, 97.27, 97.29, 97.31, 97.33, and 97.35–1 [Amended]

By amending: § 97.23 VOR, VOR/DME, VOR or TACAN, and VOR/DME or TACAN; § 97.25 LOC, LOC/DME, LDA, LDA/DME, SDF, SDF/DME; § 97.27 NDB, NDB/DME; § 97.29 ILS, ILS/DME, ISMLS, MLS/DME, MLS/RNAV; § 97.31 RADAR SIAPs; § 97.33 RNAV SIAPs; and § 97.35 COPTER SIAPs, Identified as follows:

Effective Upon Publication

FDC date	State	City	Airport	FDC No.	Subject
03/27/02	NJ	Newark	Newark Intl	2/2526	ILS Rwy 22, Amdt 11...
03/28/02	NJ	Newark	Newark Intl	2/2549	ILS Rwy 4R, Amdt 12...
04/23/02	KY	Owensboro	Owensboro-Davies County	2/3378	ILS Rwy 36, Amdt 8...
04/24/02	IL	Morris	Morris Muni-James R. Washburn Field	2/3418	VOR–A, Orig...
04/24/02	GA	Brunswick	Malcolm McKinnon	2/3428	GPS Rwy 4, Orig...
04/24/02	GA	Brunswick	Malcolm McKinnon	2/3430	VOR Rwy 4, Amdt 15...
04/24/02	GA	Brunswick	Malcolm McKinnon	2/3431	NDB Rwy 22, Orig...
04/24/02	GA	Brunswick	Malcolm McKinnon	2/3432	NDB Rwy 4, Orig–A...
04/24/02	GA	Brunswick	Malcolm McKinnon	2/3434	GPS Rwy 22, Orig...
04/25/02	VA	Richmond/Ashland	Hanover County Muni	2/3466	Loc Rwy 16, Amdt 2...
04/25/02	VA	Richmond/Ashland	Hanover County Muni	2/3476	GPS Rwy 16, Amdt 1A. This replaces FDC 2/3383 in TL02–11...
04/26/02	OR	Salem	McNary Field	2/3493	LOC BC Rwy 13, Amdt 6B...
04/26/02	MT	Butte	Bert Mooney	2/3510	ILS Rwy 15, Amdt 5A...
04/26/02	MT	Butte	Bert Mooney	2/3521	RNAV (GPS) Rwy 15, Orig...
04/30/02	OR	Pendleton	Eastern Oregon Regional at Pendleton	2/3602	ILS Rwy 25, Amdt 23...
04/30/02	TN	Sevierville	Gatlinburg-Pigeon Forge	2/3609	VOR/DME or GPS Rwy 10, Amdt 5...
04/30/02	OR	Corvallis	Corvallis Muni	2/3628	ILS Rwy 17, Amdt 3...
05/01/02	TX	Cleveland	Cleveland Muni	2/3661	GPS Rwy 16, Orig–A...
05/01/02	TX	Mineral Wells	Mineral Wells	2/3662	NDB Rwy 31, Amdt 2...
05/01/02	TX	Mineral Wells	Mineral Wells	2/3663	VOR Rwy 31, Amdt 10...
05/01/02	TX	Mineral Wells	Mineral Wells	2/3664	GPS Rwy 31, Orig...
05/02/02	GA	Tifton	Henry Tift-Myers	2/3679	VOR or GPS Rwy 27, Amdt 9B...
05/02/02	AK	Middleton Island	Middleton Island	2/3684	NDB–A, Orig...
05/03/02	MN	Cook	Cook Muni	2/3702	NDB or GPS Rwy 31, Amdt 1A...
05/08/02	CO	Monte Vista	Monte Vista Muni	2/3835	NDB Rwy 20, Orig...
05/08/02	AK	Emmonak	Emmonak	2/3891	VOR Rwy 16, Orig...
05/08/02	AK	Emmonak	Emmonak	2/3892	VOR Rwy 34, Orig...
05/08/02	AK	Anchorage	Ted Stevens Anchorage Intl	2/3903	OR Rwy 6R, Amdt 12C...

[FR Doc. 02–12287 Filed 5–15–02; 8:45 am]
BILLING CODE 4910–13–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

21 CFR Part 558

New Animal Drugs for Use in Animal Feeds; Diclazuril

AGENCY: Food and Drug Administration, HHS.

ACTION: Final rule.

SUMMARY: The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect approval of a new animal drug application (NADA) filed by Schering-Plough Animal Health Corp. The NADA provides for use of approved single-ingredient diclazuril, bacitracin methylene disalicylate, and roxarsone Type A medicated articles to make three-way combination drug Type C medicated feeds for broiler chickens.

DATES: This rule is effective May 16, 2002.

FOR FURTHER INFORMATION CONTACT: Charles J. Andres, Center for Veterinary Medicine (HFV–128), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301–827–1600, e-mail: candres@cvm.fda.gov.

SUPPLEMENTARY INFORMATION: Schering-Plough Animal Health Corp., 1095 Morris Ave., P.O. Box 3182, Union, NJ 07083, filed NADA 141–190 that provides for use of CLINACOX (0.2 percent diclazuril), BMD (10, 25, 30, 40, 50, 60, or 75 grams per pound (g/lb) bacitracin methylene disalicylate), and 3–NITRO (45.4, 90, 227, or 360 g/lb roxarsone) Type A medicated articles to make combination drug Type C medicated feeds for broiler chickens. The Type C feeds contain 0.91 g/ton diclazuril, 50 or 100 to 200 g/ton bacitracin methylene disalicylate, and 22.7 to 45.4 g/ton roxarsone and are used for the prevention of coccidiosis caused by *Eimeria tenella*, *E. necatrix*, *E. acervulina*, *E. brunetti*, *E. mitis (mivati)*, and *E. maxima*; as an aid in the prevention (at 50 g/ton bacitracin) or control (at 100 to 200 g/ton bacitracin) of necrotic enteritis caused or complicated by *Clostridium* spp. or other organisms susceptible to bacitracin; and for increased rate of weight gain, improved feed efficiency, and improved pigmentation. The NADA is approved as of December 14, 2001, and the regulations are amended in 21 CFR 558.198 to reflect the approval.

The regulations in 21 CFR 558.76 and 558.530 are also being amended to cross-reference approved combinations. The basis of approval is discussed in the freedom of information summary.

In accordance with the freedom of information provisions of 21 CFR part 20 and 514.11(e)(2)(ii), a summary of

safety and effectiveness data and information submitted to support approval of each application may be seen in the Dockets Management Branch (HFA–305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852, between 9 a.m. and 4 p.m., Monday through Friday.

The agency has determined under 21 CFR 25.33(a)(2) that this action is of a type that does not individually or cumulatively have a significant effect on the human environment. Therefore, neither an environmental assessment nor an environmental impact statement is required.

This rule does not meet the definition of ''rule'' in 5 U.S.C. 804(3)(A) because it is a rule of ''particular applicability.'' Therefore, it is not subject to the congressional review requirements in 5 U.S.C. 801–808.

List of Subjects in 21 CFR Part 558

Animal drugs, Animal feeds.

Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21 CFR part 558 is amended as follows:

PART 558—NEW ANIMAL DRUGS FOR USE IN ANIMAL FEEDS

1. The authority citation for 21 CFR part 558 continues to read as follows:

Authority: 21 U.S.C. 360b, 371.

2. Section 558.76 is amended by redesignating paragraphs (d)(3)(v) through (d)(3)(xvii) as paragraphs (d)(3)(vi) through (d)(3)(xviii), respectively, and by adding new paragraph (d)(3)(v) to read as follows:

§ 558.76 Bacitracin methylene disalicylate.

* * * * *

(d) * * *

(3) * * *

Diclazuril grams/ton	Combination grams/ton	Indications for use	Limitations	Sponsor
*	*	*	*	*
(iii) 0.91 (1 ppm).	Bacitracin methylene disalicylate 50 plus roxarsone 22.7 to 45.4	Broiler chickens: As in item (i) of this table; as an aid in the prevention of necrotic enteritis caused or complicated by *Clostridium* spp. or other organisms susceptible to bacitracin; for increased rate of weight gain, improved feed efficiency, and improved pigmentation.	Feed continuously as the sole ration throughout growing period. Use as sole source of organic arsenic; drug overdose or lack of water may result in leg weakness. Not for use in hens producing eggs for human consumption. Withdraw 5 days before slaughter. Bacitracin methylene disalicylate and roxarsone provided by No. 046573 in § 510.600(c) of this chapter.	000061
(iv) 0.91 (1 ppm).	Bacitracin methylene disalicylate 100 to 200 plus roxarsone 22.7 to 45.4	Broiler chickens: As in item (i) of this table; as an aid in the control of necrotic enteritis caused or complicated by Clostridium spp. or other organisms susceptible to bacitracin; for increased rate of weight gain, improved feed efficiency, and improved pigmentation.	Feed continuously as the sole ration throughout growing period. Start at first clinical signs of disease; vary dosage of bacitracin based on severity of infection; administer continuously for 5 to 7 days or as long as clinical signs persist, then reduce bacitracin to prevention level (50 grams per ton (g/ton). Use as sole source of organic arsenic; drug overdose or lack of water may result in leg weakness. Not for use in hens producing eggs for human consumption. Withdraw 5 days before slaughter. Bacitracin methylene disalicylate and roxarsone provided by No. 046573 in § 510.600(c) of this chapter.	000061
*	*	*	*	*

(v) Diclazuril alone and with roxarsone as in § 558.198.

* * * * *

3. Section 558.198 is amended by:

a. Revising paragraph (a);

b. Redesignating paragraph (b) as paragraph (c);

c. Adding new paragraph (b);

d. Redesignating paragraphs (d)(1)(iii) through (d)(1)(v) as paragraphs (d)(1)(v) through (d)(1)(vii), respectively; and

e. Adding new paragraphs (d)(1)(iii) and (d)(1)(iv).

The revisions and additions are to read as follows:

§ 558.198 Diclazuril.

(a) *Specifications.* Type A medicated article containing 0.2 percent diclazuril.

(b) *Approvals.* See No. 000061 in § 510.600(c) of this chapter.

* * * * *

(d) * * *

(1) * * *

* * * * *

4. Section 558.530 is amended by revising paragraph (d)(5)(x) to read as follows:

§ 558.530 Roxarsone.

* * * * *

(d) * * *

(5) * * *

(x) Diclazuril alone or in combination as in § 558.198.

* * * * *

Dated: March 15, 2002.

Stephen F. Sundlof,

Director, Center for Veterinary Medicine.

[FR Doc. 02–10963 Filed 5–15–02; 8:45 am]

BILLING CODE 4160–01–S

DEPARTMENT OF STATE

22 CFR Parts 22 and 51

[Public Notice 4016]

Schedule of Fees for Consular Services, Department of State and Overseas Embassies and Consulates

AGENCY: Department of State.

ACTION: Final rule.

SUMMARY: This rule adopts as final the Department's proposed rule to revise the Schedule of Fees for Consular Services. No comments were received during the period for public comment. The proposed rule is therefore adopted as final. The rule also made appropriate implementing and other related changes in affected portions set forth in these regulations. Specifically, the proposed rule made changes in the Schedule of Fees for Consular Services (''Schedule of Fees'' or ''Schedule'') and made technical changes concerning passport fees. The primary objective of the adjustments to the Schedule of Fees is to ensure that the costs of consular services are recovered through user fees to the maximum extent appropriate and permitted by law. As a result of new data on the cost of services, most fees are being increased. The proposed Schedule lowers the notarial fee by shifting some of the costs of this service to appropriations. In addition, the Schedule of Fees is being restructured and streamlined, making the Schedule easier to read and understand. Some services have been removed from the Schedule; in most cases, this is because services have been consolidated. Certain consular services performed for no fee are included in the Schedule so that members of the public will be aware of significant consular services provided by the Department that they may request and for which they will not be charged. Codes are being added to the Schedule to facilitate consular officers' use of the Department's consular accounting codes when the fees are actually collected.

EFFECTIVE DATE: June 1, 2002.

ADDRESSES: Office of the Executive Director, Bureau of Consular Affairs, Department of State, Suite H1004, 2401 E Street NW., Washington, DC 20520. 20520.

FOR FURTHER INFORMATION CONTACT: Susan Abeyta, Office of the Executive Director, Bureau of Consular Affairs, phone (202) 663–2505, telefax: (202) 663–2499; e-mail: *fees@state.gov.*

SUPPLEMENTARY INFORMATION:

Background

The majority of the Department of State's consular fees are established pursuant to the general user charges statute, 31 U.S.C. 9701, and/or U.S.C. 4219, which, as implemented through Executive Order 10718 of June 27, 1957, authorizes the Secretary of State to establish fees to be charged for official services provided by embassies and consulates. Fees established under these authorities include fees for immigrant and nonimmigrant visa processing, for fingerprints, and for overseas citizens services. In addition, a number of statutes address specific fees: Passport application fees (including the cost of passport issuance and use) are authorized by 22 U.S.C. 214, as are fees for the execution of passport applications. (This provision was amended on November 29, 1999, by Public Law 106–113, to permit collection of a nonrefundable application fee subject to promulgation of implementing regulations, which are at 22 CFR parts 51 and 53.) Section 636 of the Illegal Immigration Reform and Immigrant Responsibility Act of 1996, Public Law 104–208, 110 Stat. 3009–703–704 (Sept. 30, 1996), authorizes establishment of a diversity visa application fee to recover the full costs of the visa lottery conducted pursuant to Sections 203 and 222 of the Immigration and Nationality Act (''INA''), 8 U.S.C. 1153, 1202. Nonimmigrant visa reciprocity fees are authorized and, in fact, generally required, pursuant to Section 281 of the INA, 8 U.S.C. 1351. Notwithstanding the general rule of reciprocity, however, a cost-based, nonimmigrant visa processing fee for the machine readable visa (MRV) and for a combined border crossing and nonimmigrant visa card (BCC) (22 CFR 41.32) is authorized by Section 140(a) of the Foreign Relations Authorization Act, Fiscal Years 1994 and 1995, Public Law 103–236 (April 30, 1994). Certain persons are exempted by law or regulation from payment of specific fees. These exemptions are noted in the fee schedule and include the nonimmigrant visa fee exemptions set forth in 22 CFR 41.107 for certain individuals who engage in charitable activities or who qualify for diplomatic visas. In addition, aliens under age 15 are in certain circumstances entitled to a combined MRV/BCC for a statutorily established fee of $13, which is below the full cost of service, pursuant to Section 410 of Title III of the Commerce, Justice, State Appropriations Act enacted as part of the Omnibus FY 1999 Appropriations Act, Public Law 105–277 (Oct. 21, 1998). Various statutes also permit the Department to retain some of the consular fees it collects. These are, at present, the MRV and BCC fees, the passport expedite fee, the fingerprint fee, the J Visa Waiver fee, and the Diversity Visa Lottery fee. Authority to retain the Affidavit of Support fee has existed in the past and may be renewed.

With the exception of nonimmigrant visa reciprocity fees, which are established based on the practices of other countries, all consular fees are established on a basis of cost and in a manner consistent with general user charges principles, regardless of the specific statutory authority under which they are promulgated. As set forth in OMB Circular A–25, the general policy underlying user charges is that a reasonable charge should be made to each identifiable recipient for a measurable unit or amount of government service or property from which the user derives a special benefit. The OMB guidance covers all Federal Government activities that convey special benefits to recipients beyond those that accrue to the general public. The Department of State is required to review consular fees periodically to determine the appropriateness of each fee in light of applicable provisions of OMB Circular A–25. While services of direct benefit to individuals, organizations or groups should be paid for by the users rather than by taxpayers in general, the guidelines state that services performed for the primary benefit of the general public or the U.S. Government should be supported by tax revenues. The changes set forth in the proposed Schedule of Fees reflect these guidelines.

The last major revision of the Schedule of Fees was in 1998. Consistent with OMB Circular A–25, from September 1999 to October 2001, the Department conducted a cost-of-service study to determine the current direct and indirect costs associated with each consular service the Department provides, so that the Schedule could be